Takeover of terraplasma medical GmbH by the Viromed Group

The majority takeover of terraplasma medical GmbH by Viromed Plasma GmbH, a member of the Viromed Group, was announced today. terraplasma GmbH will continue to hold shares in terraplasma medical GmbH in order to contribute its expertise in the field of cold atmospheric plasmas in the future. The common goal of Viromed and terraplasma is to establish terraplasma medical as the world`s leading company and innovation leader for medical devices using cold atmospheric plasma in a wide range of medical applications.

Cold atmospheric plasma inactivates bacteria, multi-resistant pathogens, viruses and also fungi by means of highly effective physicochemical processes. It can revolutionize, supplement and in some cases even replace conventional treatment methods in medical technology, e.g., in surgery to prevent infections in post-operative wounds.

In nursing service, cold atmospheric plasma offers a therapeutic option to treat chronic and hard to heal wounds.

Cold plasma treatment reduces the use of antibiotics or cortisone and does not cause allergic side effects or pain. The plasma care® product line by terraplasma medical GmbH specifically developed for the use of cold atmospheric plasma in medical technology, will be further expanded in the future. Recent clinical experience in this field has shown that, apart from its bactericidal and healing effect, this new form of therapy offers further advantages for the health care system: e.g., a reduction in nursing and dressing costs or and - when used postoperatively -, the prevention of complications and prolonged hospital stays.

The reduced use of antibiotics can avoid resulting resistances and, in dermatology, fewer antiinflammatory drugs can be used.
Ultimately, patients` quality of life is significantly improved by successful therapy, e.g. in case of diabetic
foot or open leg.

Viromed`s involvement will significantly intensify and further strengthen the existing, very successful cooperation. This is especially important for the broad marketing of the plasma care® product range, explains Uwe Perbandt. Viromed Group is owned by the Perbandt family acting through its holding company, Perbamed Invest GmbH.

Jens Kirsch, CEO of terraplasma medical GmbH, is pleased to gain an extremely strong sales and financial partner with Viromed Group.
Dr. Julia Zimmermann, CEO of terraplasma GmbH, a spin-off of the Max Planck Society, is enthusiastic about cooperating with terraplasma medical GmbH to further develop innovative medical products for various medical applications and to establish them successfully in the market.

The departing shareholders of the investor group of Kuenheim Familiaris GmbH feel proud of having accompanied a business development that has been so successful, says Fabian von Kuenheim.

Terraplasma medical GmbH, based in Garching near Munich, was founded in 2016 by terraplasma GmbH, a spin-off from the Max Planck Society. The idea: Use of the antimicrobial and tissueregenerating effect of cold plasma in medicine and care with a small, handy device for stationary and mobile use. In 2019 the plasma care® was approved for the treatment of chronic wounds, in 2021 the plasma derma care® for the treatment of skin diseases induced by bacteria and fungi. The plasma intensive care, a device for reducing the bacterial load in the oropharynx in ventilated intensive care patients, is currently in the approval process.

The Viromed Group, based in Pinneberg near Hamburg, has been producing disinfection devices with the aid of plasmas and ionization for professional use in hospitals and practices for over 15 years and is recommended as the only manufacturer by the German Association of Pneumologists and Respiratory Medicine. Viromed commissioned SARS virus studies in security laboratories as early as 2005 and has since become the German market leader in pandemic control with products for hygienic protective measures, among other things. Masks, disinfection devices for diagnostics, etc. Rapid antigen tests, point-of-care antibody determination and real-time PCR test (rRT-PCR) as well as for digital networking. Viromed has a sales network with over 1,100 hospitals, over 2,000 old people`s homes as well as 7,000 pharmacies and 12,000 medical practices. The Viromed Group is also the main supplier of antigen tests and room fans in many federal states, federal ministries and many large DAX companies.